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Background: Transglutaminase 2 (TG2) is a post-translational protein-modifying enzyme that catalyzes the
transamidation reaction, producing crosslinked or polyaminated proteins. Increased TG2 expression and activity
have been reported in various inflammatory conditions, such as rheumatoid arthritis, inflammation-associated
pulmonary fibrosis, and autoimmune encephalitis. In particular, TG2 from epithelial cells is important during the
initial inflammatory response in the lung. In this study, we evaluated the role of TG2 in the pathogenesis of allergic
asthma, particularly whether TG2 affects initial activation signaling leading to Th2 differentiation against antigens.
Methods: We induced allergic asthma by ovalbumin sensitization and intranasal challenge in wild-type (WT) BALB/c
and TG2-deficient mice. Broncheoalveolar lavage fluid cells and intracellular cytokine production were analyzed by
flow cytometry. Interleukin (IL)-33 and TG2 expression in lung epithelial cells was detected by confocal microscopy.
Results: Airway responsiveness was attenuated in TG2-deficient mice compared to that in the WT control. In
addition, recruitment of eosinophils and Th2 and Th17 differentiation decreased in TG2-deficient mice. Treatment
with cysteamine, a transglutaminase inhibitor, also reduced airway hypersensitivity, inflammatory cell recruitment,
and T helper cell differentiation. TG2-deficient mice showed reduced IL-33 expression following induction of allergic
asthma compared to those in the WT control.
Conclusions: We found that pulmonary epithelial cells damaged by allergens triggered TG2-mediated IL-33
expression leading to type 2 responses by recruiting both innate and adaptive arms of the immune system.
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Allergic asthma is characterized by airway hyperreactivity,
mucus hypersecretion, eosinophilic infiltration, and ele-
vated serum IgE levels [1]. Although the early proposed
role of abnormal airway smooth muscles has not been
clearly defined, infiltration of inflammatory cells such as
eosinophils, macrophages, and lymphocytes in the airways
of patients with asthma and the efficacy of corticosteroids
in the majority of patients indicate that asthma is a* Correspondence: dlee5522@snu.ac.kr
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reproduction in any medium, provided the orchronic airway inflammatory disease [2]. T cells play an
important role during asthma pathogenesis, and T helper
type 2 (Th2) cell differentiation is important in initiating
and perpetuating events in asthma, particularly in experi-
mental models [1,2]. The role of innate inflammatory cells,
such as mast cells, basophils, and recently defined innate
lymphoid cells, has been suggested to provide a local cyto-
kine environment that induces Th2 differentiation [3]. In
addition, epithelial cells at the mucosal surfaces have been
accepted as integral components of innate and adaptive
immunity [4,5]. The important role of pulmonary epithe-
lial cells during lung infection has been documented [5-7],
and the critical role of epithelial cells in inflammatory. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cently been reported by our group [8].
Transglutaminase 2 (TG2) is a post-translational pro-
tein-modifying enzyme that catalyzes the transamidation
reaction, producing crosslinked or polyaminated proteins.
TG2 is expressed ubiquitously in various cellular compart-
ments and participates in many biological processes, in-
cluding extracellular matrix formation, wound healing,
apoptosis, and differentiation [9,10]. TG2 has also been
implicated in many disease processes. Increased TG2 ex-
pression and activity have been reported in various inflam-
matory conditions, such as rheumatoid arthritis, gouty
arthritis, and organ fibrosis [11-13]. Altered forms of
proteins modified by TG2 enzymatic activity have been
suggested in the pathogenesis of various diseases, such
as celiac disease, cataracts, and Huntington’s disease
[9,10,14-16]. Controversies exist regarding the pathological
and protective roles of TG2 during inflammation, TG2
sustains inflammation through the release of inflammatory
cytokines while minimizing inflammation by increasing the
clearance of apoptotic cells [12,17]. Recent disease animal
models using TG2-deficient mice have revealed the im-
portant role of TG2 during the pathogenesis of bacterial
sepsis, inflammation-associated pulmonary fibrosis, and
autoimmune encephalitis [8,18,19]. TG2 is important du-
ring the initial inflammatory response. Specifically, TG2 in-
duces nuclear factor-κB-dependent interleukin (IL)-6
secretion from lung epithelial cells, leading to Th17 diffe-
rentiation in the lung [8]. Epithelial cell-derived signaling
mediators, such as IL-33, thymic stromal lymphopoietin
(TSLP), and IL-25, initiate Th2 immune responses and
each can direct the Th2 response either alone or through
downstream mediators [4]. Among these, IL-33 has been
implicated as the most upstream mediator of epithelial
cytokines [4]. Since epithelial TG2 can initiate the in-
flammatory response of non-infectious tissue damage [8],
we assumed the TG2 may also play an important role in initi-
ating and perpetuating the epithelial inflammatory response
leading to Th2 differentiation.
In this study, we investigated the role of TG2 in the
pathogenesis of allergic asthma, particularly whether TG2
affects initial activation signaling by inducing IL-33 and
downstream molecules leading to Th2 differentiation
against antigens. Allergic asthma was induced by ovalbu-
min (OVA) sensitization and intranasal challenge. We
found that airway hypersensitivity was attenuated in TG2-
deficient mice compared to that in wild-type (WT) con-
trols and recruitment of eosinophils and Th2 and Th17
differentiation was decreased in TG2-deficient mice. Treat-
ment with cysteamine, a transglutaminase inhibitor, also
reduced airway hypersensitivity, inflammatory cell recruit-
ment, and T helper cell differentiation. TG2-deficient mice
revealed decreased IL-33 expression following the induc-
tion of allergic asthma compared to that in the WTcontrol. Thus, we provide evidence that TG2 in pulmonary




BALB/c mice were obtained from the Jackson Laboratory
(Bar Harbor, ME). TG2−/− mice were backcrossed to BALB/c
mice for 12 generations (N12). Female, 8-12-week-old mice
were used for experiments. All animal experiments were
performed with the approval of the Institutional Animal
Care and Use Committee at Seoul National University
(authorization no. SNU05050203).
Immunization
Mice were intraperitoneally administered phosphate
buffered saline (PBS) containing OVA (grade V, Sigma-
Aldrich, St Louis, MO) and aluminum hydroxide (alum)
(Sigma-Aldrich) (20 μg OVA + 2 mg alum) two times at
a 7-day interval. Intranasal OVA challenge (50 μg) was
performed for 3 consecutive days starting on days 14
and 21 after the first immunization. Mice were injected
intraperitoneally with cysteamine (40 mg/kg/day, Sigma-
Aldrich) to inhibit TG2 activity.
Airway responsiveness
Airway responsiveness was assessed as a change in airway
function after challenge with aerosolized methacholine
(Sigma-Aldrich) via the airways. Mice progressively in-
haled 6.25–50 mg/ml methacholine for 5 min at 24 h
after the last OVA intranasal challenge. Airway respon-
siveness was measured using the OCP3000 instrument
(One Chamber Plethysmography for animals; Allmedicus,
Anyang, Gyeonggi-do, Korea).
Histopathology and immunofluorescence of lung tissue
Lung tissues were fixed in 4% paraformaldehyde, pro-
cessed, and embedded in paraffin. Sections were stained
with H&E for histopathological analysis. To investigate
IL-33 expression in epithelial cells, lung tissue from
airway hypersensitivity-induced mice were stained with
anti-IL-33 (R&D Systems, Minneapolis, MN), anti-TG2
(Neomarker, Fremont, CA), and anti-pro-surfactant
protein-C (pro-SP-C, Millipore, Billerica, MA). Alexa 488-
conjugated donkey anti-goat IgG and Alexa 546-conjugated
anti-rabbit IgG antibodies (Invitrogen, Carlsbad, CA) were
used for visualization. Image acquisition and processing
was performing using a confocal fluorescence microscope
(Olympus, Center Valley, PA) and FV10-ASW 2.0 Viewer
(Olympus).
Analysis of broncheoalveolar lavage fluid (BALF)
Broncheoalveolar lavage was performed with five 1.0-mL
aliquots of PBS through a tracheal cannula. Cytospin
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Wright-Giemsa. BALF were analyzed for IL-13 and IL-17
and IL-4 and IFN-γ levels by sandwich ELISA. To evaluate
cytokine production, cells were restimulated with 50 ng/ml
PMA and 1 μg/ml ionomycin (Sigma-Aldrich) for 4 h. For
intracellular staining, Golgi plug (BD-Pharmingen, San
Diego, CA) was added during the final 2 h of stimulation.
Cells were labeled with anti-CD4, anti-IL-4, anti-IL-13,
anti-IL-17, and anti-IFN-γ antibodies (eBioscience, San
Jose, CA). Intracellular cytokine levels were analyzed
using a FACSCalibur (BD Biosciences, San Jose, CA) and
FlowJo software (Tree Star, Ashland, OR).
Statistical analysis
Statistical significance was analyzed using the Student’s
t-test. A p value of < 0.05 was taken to indicate statis-
tical significance.
Results
Airway inflammation was attenuated in TG2-deficient mice
WT BALB/c and TG2-deficient mice with a BALB/c
background (N12) (TG2−/−) were intraperitoneally admi-
nistered OVA and alum (20 μg OVA + 2 mg alum) twoFigure 1 Transglutaminase 2 (TG2) deficiency attenuates airway hype
immunized with ovalbumin (OVA) plus aluminum hydroxide (alum) and int
expression in the lungs from WT mice. Sections were prepared 24 h after in
Representative photographs of lungs from WT and TG2−/− mice after sensi
hematoxylin and eosin (original magnification, ×100). (D) Airway responsive
recorded for 3 min after aerosol methacholine treatment. The results for eatimes at a 7-day interval, and an intranasal OVA challenge
(50 μg OVA) for 3 consecutive days starting on days 14 and
21 to evaluate the role of TG2 during the pathogenesis of
allergic asthma. Airway hyperresponsiveness (AHR) was
assessed by methacholine challenge 1 day following the
last intranasal OVA challenge, and the whole body
method was used to measure enhanced pause. Broncho-
alveolar lavage (BAL) fluid and lung tissue were sampled
the next day (Figure 1A). TG2 expression from paren-
chymal lung tissue, especially from type II alveolar cells
increased in OVA-immunized and -challenged mice com-
pared to that in unmanipulated control mice (Figure 1B).
The histopathological analysis of lung tissue following
disease induction revealed that TG2−/− mice had reduced
airway inflammation with decreased inflammatory cell in-
filtration surrounding the airways as compared with WT
mice (Figure 1C). Airway hyperresponsiveness also de-
creased in TG2 mice compared to that in WT mice
(Figure 1D).
Recruitment of eosinophils is reduced in TG2-deficient mice
OVA-sensitized and –challenged WT mice showed in-
creased numbers of inflammatory cells in BAL fluidrsensitivity. (A) Wild-type (WT) and TG2 deficient (TG2−/−) mice were
ranasally challenged with OVA. (B) Immunohistochemistry of TG2
tranasal OVA challenge (original magnification, ×400). (C)
tization and challenge with PBS or OVA. Sections were stained with
ness was measured in sensitized and challenged mice. Pause was
ch group are expressed as means ± standard errors (n = 5).
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addition, TG2−/− mice showed decreased inflammatory
cell infiltration compared to that in WT mice (Figure 2A).
Cytospin analysis with Wright–Giemsa stain revealed that
TG2−/− mice showed a dramatic decrease in eosinophils,
but not macrophages or lymphocytes, in BAL fluid. Thus,
the reduction in infiltrating inflammatory cells in these
mice reflected selective reduction of eosinophils (Figure 2B
and 2C). We also confirmed a selective decrease of eosin-
ophils in the TG2−/− mice as compared with WT mice
using flow cytometric analysis of BAL fluid (Figure 2D).
Reduced Th2/Th17 differentiation in TG2-deficient mice
Intracellular cytokine analysis of BAL fluid cells from OVA
exposed mice revealed that TG2−/− mice showed decreased
amounts of IL-4- and/or IL-13-secreting CD4+ T cells
compared to WT mice (Figure 3A). IL-4, IL-13, IL-17, and
OVA-specific-IgE levels in the BAL fluid decreased,Figure 2 Transglutaminase 2 (TG2) deficiency reduces eosinophil recr
−/− mice was obtained 48 h after the last OVA challenge. BAL cells were co
differential cell counts (B) were performed. (C) Representative photographs
magnification, ×1000). Arrows present eosinophils. (D) Inflammatory cells in
anti-Siglec-F antibodies and analyzed by flow cytometry. (A-B) Data are me
BAL cells from n = 5 mice/group.whereas interferon (IFN)-γ increased, in TG2−/− mice
compared to WT mice (Figure 3B).Cysteamine treatment reduced recruitment of airway
inflammatory cells
We intraperitoneally injected cysteamine twice daily
(40 mg/kg) from the day of the first intraperitoneal OVA
sensitization to evaluate the effect of the transglutaminase
pharmacological inhibitor on the pathogenesis of allergic
asthma. Cysteamine treatment decreased airway inflam-
mation compared to that in the PBS-treated control
(Figure 4A). The BAL fluid analysis revealed that cyste-
amine greatly reduced the number of infiltrating inflam-
matory cells compared to the PBS-treated control
(Figure 4B). The decrease in inflammatory cells was not
confined to eosinophils, as cysteamine treatment reduced
all components of innate and adaptive cells recruited touitment. (A–C) Bronchoalveolar lavage (BAL) fluid from WT and TG2
unted and analyzed by Wright-Giemsa staining. Total (A) and
of BAL cells. Cells were stained with Wright–Giemsa (original
BAL fluid from WT and TG2−/− mice were labeled with anti-CCR3 and
ans ± standard deviation of three independent determinations with
Figure 3 TG2 deficiency reduces Th2 and Th17 differentiation. (A) BAL cells were harvested 48 h after the last OVA challenge and
restimulated with phorbol myristic acid (PMA) and ionomycin for 4 h. Intracellular cytokine levels were analyzed by flow cytometry. (B) Levels of
interleukin (IL)-4, IL-13, IL-17, and interferon (IFN)-γ in BAL fluid were determined by ELISA. OVA-specific IgE in BAL fluid was also detected by
ELISA. Data are means ± standard deviations of three independent determinations with BAL cells from n = 5 mice/group.
Figure 4 Cysteamine treatment reduces airway hypersensitivity. (A-C) WT mice were immunized with OVA plus alum and intranasally
challenged with OVA. Mice were injected intraperitoneally with cysteamine (40 mg/kg/day) to inhibit TG2 activity. (A) Representative photographs
of lungs from PBS- or cysteamine-treated mice. Sections are stained with hematoxylin and eosin (original magnification, ×200). (B, C) BAL fluid
was obtained 48 h after the last challenge with OVA. BAL cells were counted and analyzed by Wright–Giemsa staining. Total (B) and differential
cell counts (C) were performed. Data are means ± standard deviations of three independent determinations with BAL cells from
n = 5 mice/group.
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phocytes (Figure 4C).
Cysteamine treatment reduced T helper cell
differentiation
Cysteamine (CyM) treatment reduced all cytokine-
secreting lymphocytes tested when we analyzed BAL
fluid infiltrating lymphocytes using intracellular cytokine
staining. Not only IL-4-, IL-13-, and IL-17-secreting
lymphocytes, but also IFN-γ-secreting lymphocytes de-
creased in percentage and number compared to those in
the PBS-treated control (Figure 5A and 5B). T helper
cell differentiation to all pathways tested also decreased
following cysteamine treatment when we gated CD4+
T cells (Figure 5A and 5C). We assessed IL-33 expression
from pulmonary epithelial cells following disease induc-
tion to evaluate the role of TG2 during the initiation of
Th2 differentiation and airway hyperresponsiveness, as
IL-33 has been implicated as the most upstreamFigure 5 Cysteamine treatment reduces T helper cell differentiation. B
restimulated with phorbol myristic acid (PMA) and ionomycin for 4 h. Intra
proportions of interleukin (IL)-4-, IL-13-, IL-17-, and interferon (IFN)-γ-produc
Number of cytokine-producing CD4+ T cells. (D) Immunofluorescence stain
lungs from PBS or CyM-treated WT mice. Sections were prepared 24 h afte
(A-C) Data are means ± standard deviations of three independent determinepithelial cytokine mediator leading to the Th2 pheno-
type [16]. PBS-treated WT mice revealed increased IL-33
expression in pulmonary epithelial cells following intra-
nasal OVA challenge, whereas CyM-treated mice showed
reduced IL-33 expression (Figure 5D).Reduced IL-33 expression in TG2-deficient mice
WT mice revealed increased IL-33 expression in pulmon-
ary epithelial cells, whereas TG2−/− mice showed reduced
IL-33 expression (Figure 6A). The kinetics of IL-33 ex-
pression also showed delayed and reduced IL-33 expres-
sion in TG2−/− mice compared to WT mice (Figure 6A).
Reduced IL-33 expression in the TG2−/− mice was also re-
vealed by reverse transcription polymerase chain reaction
(RT-PCR) analysis of the lung. TG2−/−mice also showed re-
duced TSLP expression compared to WT mice (Figure 6B).
Th2 responses occurred in the wild-type mice only fol-
lowing 4 times or more of intranasal OVA challenges,AL cells were harvested 48 h after the last OVA challenge and
cellular cytokine levels were analyzed by flow cytometry. (A) The
ing cells are shown. (B) Number of cytokine-producing cells. (C)
ing of IL-33 (green) and pro-surfactant protein C (SPC) (red) in the
r the last ovalbumin (OVA) challenge (original magnification, ×1000).
ations with BAL cells from n = 5 mice/group.
Figure 6 Reduced IL-33 in TG2−/− mice. (A) Immunofluorescence staining of IL-33 (green) and pro-SPC (red) in the lung from WT and TG2−/−
mice. Sections were prepared 24 h after OVA challenge. (original magnification, ×1000). (B) IL-33 mRNA expression in lung tissues of WT and
TG2−/− mice were determined by reverse transcription-polymerase chain reaction. (C) BAL cells were harvested 24 h after OVA challenge and
restimulated with PMA and ionomycin for 4 h. Intracellular cytokine levels were analyzed by flow cytometry. The proportions of IL-4- and
IL-13-producing cells are shown.
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33 expression reached its peak level (Figure 6C).
Discussion
In this study, we observed that TG2 plays an important
role in initiating the allergic Th2 response by inducing
IL-33 and downstream molecules leading to Th2 differ-
entiation following allergen sensitization and challenge.
Airway hyperresponsiveness was attenuated in TG2-
deficient mice compared to WT control mice, and
recruitment of eosinophils and Th2 and Th17 differenti-
ation decreased in TG2-deficient mice. We confirmed
the role of TG2 in the pathogenesis of allergic asthma
using cysteamine, a transglutaminase inhibitor. TG2-
deficient mice revealed reduced IL-33 expression follow-
ing asthma induction. Thus, we provide evidence that
TG2 in pulmonary epithelial cells initiates allergic re-
sponses through the IL-33-Th2 signaling pathways.
The roles of TG2 in the pathogenesis of organ-specific
and systemic inflammatory responses including hyper-
sensitivity reactions have been documented. Cysteamine,a broad-spectrum transglutaminase inhibitor, reduces pul-
monary inflammation and fibrosis following intratracheal
bleomycin instillation [8]. Cystamine, a dimeric form of
cysteamine, also ameliorates IgE-induced passive cutane-
ous anaphylaxis and phorbol myristic acid-induced atopic
dermatitis [20]. Sohn et al. [21] developed recombinant
peptides with dual inhibitory capacity against TG2 and
phospholipase A2, and these recombinant peptides
reversed the inflammation of allergic conjunctivitis. These
authors also found that R2 peptide treatment ameliorates
inflammatory allergic asthma induced by OVA sensi-
tization and challenge [22]. A correlation between TG2
expression and disease progression has been suggested in
patients with toluene diisocyanate-induced occupational
asthma and exercise-induced bronchoconstriction [23,24].
Although an important role for TG2 in allergic asthma
pathogenesis has been suggested by these reports, all stud-
ies used rather nonspecific pharmacological inhibitors or
conducted relative expression studies. Therefore, the crit-
ical role of TG2 during asthma pathogenesis has not been
properly evaluated using genetically modified mice. In this
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critical role for TG2 during the pathogenesis of experi-
mental allergic asthma and suggest that TG2 is a putative
novel disease target of allergic asthma.
Asthma is a chronic inflammatory disease with charac-
teristics of type 2 cytokine production. IL-33 is a strong
inducer of the Th2 immune response, and its role in the
immunopathogenesis of allergic asthma had been docu-
mented. Higher IL-33 expression occurs in patients with
asthma and in murine models of asthma [25,26]. In-
creased airway hyper-responsiveness and inflammatory
cell infiltration is observed by either IL-33 administration
or by studies with IL-33 overexpressing transgenic
[27,28]. IL-33-deficient mice reveal reduced inflammatory
cell recruitment to the lung and attenuated airway hyper-
responsiveness compared to that of a WT control [29]. In
addition, blocking ST2 signaling either by blocking anti-
bodies or by using a soluble receptor protein inhibits pul-
monary inflammation and airway hyperresponsiveness
[30]. IL-33 induces type 2 cytokine production through
the ST2 receptor expressed on multiple innate and adap-
tive immune cells, including type 2 innate lymphoid cells,
Th2 cells, mast cells, basophils, eosinophils, and natural
killer T cells [31]. Further, IL-33 stimulates the expres-
sion of TSLP and its receptor and, thus, indirectly in-
duces Th2 responses [4,32], which was also reduced in
TG2-deficient mice in our study. Data on the IL-33 in-
duction signaling pathway are incomplete, but a recent
report revealed a role for extracellular ATP in triggering
IL-33 release following airborne allergen exposure [33].
In our study, expression of IL-33 increased in the type
II pulmonary epithelial cells following intranasal OVA
treatment and increased further following additional in-
tranasal injection of OVA (Figure 6A). TG2 expression
on the pulmonary epithelial cells also increased by intra-
nasal OVA injection and further increased with additional
OVA challenge, which closely paralleled IL-33 expression
kinetics. Among the several suggested mechanisms of
TG2, transglutaminase enzyme activity may be involved in
the regulation of IL-33 expression in that inhibition of en-
zyme activity using CyM also decreased IL-33 expression
comparable to TG2 knockout mice (Figure 5D). In
addition, we found that Th2 responses occurred in the
wild-type mice only following 4 times or more of intrana-
sal OVA challenges in our experimental settings, which in-
dicated the Th2 responses developed when IL-33
expression reached its peak level (Figure 6C). Thus we
suggest that TG2 and downstream IL-33 expression
seem to be important in the induction of Th2 response
and eosinophil recruitment.
The important role of lung epithelial cells in initiating
pulmonary inflammation during allergic responses re-
quires further discussion. Epithelial cells are implicated
as an important initiator and perpetuator of protectiveand pathological inflammation from both infectious and
non-infectious stimuli [34,35]. IL-33 and its ST2 recep-
tor are mainly expressed in bronchial epithelial cells in
the lung [25]. Thus, airway epithelial cells are also active
players in the pathogenesis of asthma through epithelial
cytokines including IL-33, TSLP, and IL-25, which are
produced and released by epithelial cells in response to
various exogenous stimuli or by cellular damage [36]. In
our previous report, epithelial TG2 played a critical role
in initiating the inflammatory response leading to the
type 17 response following bleomycin treatment [8].
Conclusion
In this study, we found that pulmonary epithelial cells
damaged by allergens triggered TG2-mediated IL-33 ex-
pression leading to type 2 responses by recruiting both in-
nate and adaptive arms of the immune system. Thus,
epithelial TG2 was a common critical link transducing epi-
thelial tissue damage to initiate Th2 or Th17 inflammatory
responses depending on the context of the stimuli.
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